Literature DB >> 23318470

Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease.

Briana R De Miranda1, James A Miller, Ryan J Hansen, Paul J Lunghofer, Stephen Safe, Daniel L Gustafson, Dorothy Colagiovanni, Ronald B Tjalkens.   

Abstract

There are currently no registered drugs that slow the progression of neurodegenerative diseases, in part because translation from animal models to the clinic has been hampered by poor distribution to the brain. The present studies examined a selected series of para-phenyl-substituted diindolylmethane (C-DIM) compounds that display anti-inflammatory and neuroprotective efficacy in vitro. We postulated that the pharmacokinetic behavior of C-DIM compounds after oral administration would correlate with neuroprotective efficacy in vivo in a mouse model of Parkinson's disease. Pharmacokinetics and metabolism of 1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane (C-DIM5), 1,1-bis(3'-indolyl)-1-(phenyl)methane, 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (C-DIM8), and 1,1-bis(3'-indolyl)-1-(p-chlorophenyl)methane (C-DIM12) were determined in plasma and brain of C57Bl/6 mice after oral and intravenous administration at 10 and 1 mg/Kg, respectively. Putative metabolites were measured in plasma, liver, and urine. C-DIM compounds given orally displayed the highest area under the curve, Cmax, and Tmax levels, and C-DIM12 exhibited the most favorable pharmacokinetics of the compounds tested. Oral bioavailability of each compound ranged from 6% (C-DIM8) to 42% (C-DIM12). After pharmacokinetic studies, the neuroprotective efficacy of C-DIM5, C-DIM8, and C-DIM12 (50 mg/Kg per oral) was examined in mice exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and probenecid for 14 days, a model of progressive neurodegeneration with a strong neuroinflammatory component. C-DIM5 and C-DIM12 given orally once daily after one week of exposure to MPTP and probenecid prevented further loss of dopaminergic neurons in the substantia nigra pars compacta and striatal dopamine terminals, indicating that these compounds could be effective therapeutic agents to prevent neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318470      PMCID: PMC6067390          DOI: 10.1124/jpet.112.201558

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Selective Aryl Hydrocarbon Receptor Modulator 3,3'-Diindolylmethane Impairs AhR and ARNT Signaling and Protects Mouse Neuronal Cells Against Hypoxia.

Authors:  J Rzemieniec; E Litwa; A Wnuk; W Lason; W Krzeptowski; M Kajta
Journal:  Mol Neurobiol       Date:  2015-10-17       Impact factor: 5.590

2.  Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes.

Authors:  Md Imam Uddin; Jason R Buck; Michael L Schulte; Dewei Tang; Samir A Saleh; Yiu-Yin Cheung; Joel Harp; H Charles Manning
Journal:  Tetrahedron Lett       Date:  2014-01-01       Impact factor: 2.415

Review 3.  Structure-dependent activation of gene expression by bis-indole and quinoline-derived activators of nuclear receptor 4A2.

Authors:  Xi Li; Ronald B Tjalkens; Rupesh Shrestha; Stephen Safe
Journal:  Chem Biol Drug Des       Date:  2019-07-21       Impact factor: 2.817

4.  Genetic suppression of IKK2/NF-κB in astrocytes inhibits neuroinflammation and reduces neuronal loss in the MPTP-Probenecid model of Parkinson's disease.

Authors:  Kelly S Kirkley; Katriana A Popichak; Sean L Hammond; Cecilia Davies; Lindsay Hunt; Ronald B Tjalkens
Journal:  Neurobiol Dis       Date:  2019-02-25       Impact factor: 5.996

5.  Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists.

Authors:  Erik Hedrick; Xi Li; Yating Cheng; Alexandra Lacey; Kumaravel Mohankumar; Mahsa Zarei; Stephen Safe
Journal:  Breast Cancer Res Treat       Date:  2019-05-22       Impact factor: 4.872

6.  The Nurr1 Activator 1,1-Bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane Blocks Inflammatory Gene Expression in BV-2 Microglial Cells by Inhibiting Nuclear Factor κB.

Authors:  Briana R De Miranda; Katriana A Popichak; Sean L Hammond; Bryce A Jorgensen; Aaron T Phillips; Stephen Safe; Ronald B Tjalkens
Journal:  Mol Pharmacol       Date:  2015-04-09       Impact factor: 4.436

7.  Novel para-phenyl substituted diindolylmethanes protect against MPTP neurotoxicity and suppress glial activation in a mouse model of Parkinson's disease.

Authors:  Briana R De Miranda; Katriana A Popichak; Sean L Hammond; James A Miller; Stephen Safe; Ronald B Tjalkens
Journal:  Toxicol Sci       Date:  2014-11-17       Impact factor: 4.849

8.  Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity.

Authors:  Apurva R Patel; Ravi Doddapaneni; Terrick Andey; Heather Wilson; Stephen Safe; Mandip Singh
Journal:  J Control Release       Date:  2015-06-14       Impact factor: 9.776

9.  Pharmacological Activators of the NR4A Nuclear Receptors Enhance LTP in a CREB/CBP-Dependent Manner.

Authors:  Morgan S Bridi; Joshua D Hawk; Snehajyoti Chatterjee; Stephen Safe; Ted Abel
Journal:  Neuropsychopharmacology       Date:  2016-11-11       Impact factor: 7.853

Review 10.  Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.

Authors:  Md Jakaria; Md Ezazul Haque; Duk-Yeon Cho; Shofiul Azam; In-Su Kim; Dong-Kug Choi
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.